JP2020534277A5 - - Google Patents

Download PDF

Info

Publication number
JP2020534277A5
JP2020534277A5 JP2020515175A JP2020515175A JP2020534277A5 JP 2020534277 A5 JP2020534277 A5 JP 2020534277A5 JP 2020515175 A JP2020515175 A JP 2020515175A JP 2020515175 A JP2020515175 A JP 2020515175A JP 2020534277 A5 JP2020534277 A5 JP 2020534277A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
acid sequence
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020515175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534277A (ja
JP7403441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/051166 external-priority patent/WO2019055841A1/en
Publication of JP2020534277A publication Critical patent/JP2020534277A/ja
Publication of JP2020534277A5 publication Critical patent/JP2020534277A5/ja
Priority to JP2023136384A priority Critical patent/JP2023163183A/ja
Application granted granted Critical
Publication of JP7403441B2 publication Critical patent/JP7403441B2/ja
Priority to JP2025113952A priority patent/JP2025133893A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020515175A 2017-09-14 2018-09-14 抗trem2抗体及びその使用方法 Active JP7403441B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023136384A JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762558803P 2017-09-14 2017-09-14
US62/558,803 2017-09-14
US201762583379P 2017-11-08 2017-11-08
US62/583,379 2017-11-08
US201862621380P 2018-01-24 2018-01-24
US62/621,380 2018-01-24
PCT/US2018/051166 WO2019055841A1 (en) 2017-09-14 2018-09-14 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023136384A Division JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2020534277A JP2020534277A (ja) 2020-11-26
JP2020534277A5 true JP2020534277A5 (cg-RX-API-DMAC7.html) 2021-10-14
JP7403441B2 JP7403441B2 (ja) 2023-12-22

Family

ID=63714159

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020515175A Active JP7403441B2 (ja) 2017-09-14 2018-09-14 抗trem2抗体及びその使用方法
JP2023136384A Pending JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A Pending JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023136384A Pending JP2023163183A (ja) 2017-09-14 2023-08-24 抗trem2抗体及びその使用方法
JP2025113952A Pending JP2025133893A (ja) 2017-09-14 2025-07-04 抗trem2抗体及びその使用方法

Country Status (6)

Country Link
US (1) US20200277373A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681909A1 (cg-RX-API-DMAC7.html)
JP (3) JP7403441B2 (cg-RX-API-DMAC7.html)
CN (1) CN111448212A (cg-RX-API-DMAC7.html)
CA (1) CA3075285A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019055841A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CA3120875A1 (en) 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
CN110511240B (zh) * 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
IL293018A (en) * 2019-11-22 2022-07-01 Lilly Co Eli trem2 antibodies and their uses
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
US20230265212A1 (en) * 2019-12-19 2023-08-24 Kevin S. EISENFRATS Compositions and methods for oocyte-specific contraception
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11124567B2 (en) * 2020-01-13 2021-09-21 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN115768794A (zh) 2020-02-24 2023-03-07 艾利妥 抗trem2抗体的使用方法
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
CN111793131A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中pf4含量的抗体对及其用途
CN116323667A (zh) * 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CN114075284B (zh) * 2020-08-17 2023-11-17 上海元宋生物技术有限公司 Cd47结合分子及其用途
WO2022045865A1 (ko) * 2020-08-31 2022-03-03 (주)메디톡스 항-vegf 육량체 항체, 및 이를 포함하는 조성물
US20240102094A1 (en) * 2020-12-03 2024-03-28 Amgen Inc. Trem2 agonist biomarkers and methods of use thereof
CN112526143B (zh) * 2020-12-03 2021-08-03 中山大学附属第五医院 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用
WO2022241082A1 (en) 2021-05-14 2022-11-17 Genentech, Inc. Agonists of trem2
IL308804A (en) * 2021-05-28 2024-01-01 Vigil Neuroscience Inc TREM2 agonistic biomarkers and methods of using them
CN115505041B (zh) * 2021-06-22 2026-05-05 北京免疫方舟医药科技有限公司 抗EphA2抗体及其应用
IL285416A (en) * 2021-08-05 2023-03-01 Yeda Res & Dev Antibodies for cancer treatment
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
US20240392035A1 (en) * 2021-08-25 2024-11-28 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
WO2023039612A1 (en) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Trem2 antigen binding proteins and uses thereof
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023215697A1 (en) * 2022-05-05 2023-11-09 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
JP2025529287A (ja) 2022-09-06 2025-09-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル マルファン症候群の処置のためのtrem-2アゴニスト
US20240262929A1 (en) * 2023-02-06 2024-08-08 Ibio, Inc. Anti-muc16 antibodies
WO2024250809A1 (zh) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 抗trem2全人源抗体或其抗原结合片段及其应用
AU2024320793A1 (en) 2023-08-09 2026-03-12 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
AU2024323186A1 (en) 2023-08-09 2026-01-15 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046298A2 (en) * 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
CN117534569B (zh) * 2023-11-23 2026-03-13 复旦大学附属华山医院 S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途
CN118546252A (zh) * 2024-04-02 2024-08-27 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002021141A2 (en) 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
CN102268094A (zh) 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
DK2046826T3 (da) 2006-07-24 2011-10-24 Biorexis Pharmaceutical Corp Exendin-fusionsproteiner
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
MX367126B (es) * 2012-08-29 2019-08-06 Hoffmann La Roche Transporte para atravesar la barrera hematoencefálica.
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
JP7725185B2 (ja) 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法

Similar Documents

Publication Publication Date Title
JP7403441B2 (ja) 抗trem2抗体及びその使用方法
JP7837375B2 (ja) ピログルタメートアミロイド-βに対する抗体及びその使用
CA3190581A1 (en) Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists
JP6210966B2 (ja) 抗Siglec−15抗体
ES2619709T5 (es) Agentes de unión a esclerostina
ES3059612T3 (en) Anti-alk2 antibody
US20230012428A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
JP2018531580A (ja) 過リン酸化タウに特異的な抗体およびその使用方法
EP2832855A1 (en) Novel anti-siglec15 antibody
Von Büdingen et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands”
KR20140107493A (ko) 항-phf-타우 항체 및 그의 용도
CA2724432A1 (en) Compositions and methods for binding lysophosphatidic acid
RS64386B1 (sr) Anti-n3pglu amiloid beta peptid antitela i njihova upotreba
JP2015057382A (ja) 線維症、炎症性および新血管形成症状の処置および予防のための組成物および方法
RU2014118456A (ru) Фосфоспецифичные антитела, распознающие тау
JP2018508210A (ja) タウに対する抗体およびその使用
JP2022526334A (ja) 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
CA3147020A1 (en) Anti-nampt antibodies and uses thereof
KR102385790B1 (ko) 신규한 항-Fc-감마 수용체 IIB 항체 및 이의 용도
JP2025517356A (ja) 抗cd22抗体オリゴヌクレオチドコンジュゲートを使用したがんの治療方法
US20140065154A1 (en) Tlr3 binding agents
TW202607018A (zh) 抗載脂蛋白e4(apoe4)抗體及其用途
JP7520726B2 (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体2のアンタゴニスト及びアゴニスト
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
TW202535461A (zh) 使用抗sirpa抗體治療肝臟疾病或病症